reports
Ageas reports on the progress of share buy-back programme
Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 67,895 Ageas shares in the period from 13-01-2025 until 17-01-2025. DateNumber ofSharesTotal amount(EUR)Average price(EUR)Lowest price(EUR)Highest price(EUR)13-01-202517,346805,79246.4546.0846.7214-01-202519,500914,50546.9046.6847.0615-01-202513,158626,38647.6047.2047.9416-01-20259,860473,68348.0447.8048.1817-01-20258,031390,58848.6448.4248.84Total67,8953,210,95347.2946.0848.84 Since the start of the share buy-back pro...
Rapport d’Ageas sur le programme de rachat d’actions
Rapport d’Ageas sur le programme de rachat d’actions Dans le cadre du programme de rachat d’actions annoncé le 28 août 2024, Ageas indique que 67.895 actions Ageas ont été achetées durant la période du 13-01-2025 au 17-01-2025. DateNombred’actionsMontant total(EUR)Cours moyen(EUR)Cours le plus bas (EUR)Cours le plus élevé (EUR)13-01-202517.346805.79246,4546,0846,7214-01-202519.500914.50546,9046,6847,0615-01-202513.158626.38647,6047,2047,9416-01-20259.860473.68348,0447,8048,1817-01-20258.031390.58848,6448,4248,84Total67.8953.210.95347,2946,0848,84 Depuis le lancement du programme de rachat d...
Ageas rapporteert over de inkoop van eigen aandelen
Ageas rapporteert over de inkoop van eigen aandelen Ageas rapporteert over de inkoop van eigen aandelen Naar aanleiding van het aandelen-inkoopprogramma dat op 28 augustus 2024 aangekondigd werd, maakt Ageas bekend dat er 67.895 eigen aandelen ingekocht werden tussen 13-01-2025 en 17-01-2025. DatumAantalaandelenTotaal Bedrag(EUR)Gemiddelde koers(EUR)Laagste koers(EUR)Hoogste koers(EUR)13-01-202517.346805.79246,4546,0846,7214-01-202519.500914.50546,9046,6847,0615-01-202513.158626.38647,6047,2047,9416-01-20259.860473.68348,0447,8048,1817-01-20258.031390.58848,6448,4248,84Totaal67.8953.210.95...
Ageas reports on the progress of share buy-back programme
Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 84,549 Ageas shares in the period from 06-01-2025 until 10-01-2025. DateNumber ofSharesTotal amount(EUR)Average price(EUR)Lowest price(EUR)Highest price(EUR)06-01-202517,768838,33547.1846.9647.4607-01-202516,445777,65547.2946.6647.5408-01-202517,362820,71247.2747.0647.5409-01-202515,676745,63047.5747.2647.7610-01-202517,298817,71647.2747.0047.66Total84,5494,000,04947.3146.6647.76 Since the start of the share buy-back p...
Rapport d’Ageas sur le programme de rachat d’actions
Rapport d’Ageas sur le programme de rachat d’actions Dans le cadre du programme de rachat d’actions annoncé le 28 août 2024, Ageas indique que 84.549 actions Ageas ont été achetées durant la période du 06-01-2025 au 10-01-2025. DateNombred’actionsMontant total(EUR)Cours moyen(EUR)Cours le plus bas (EUR)Cours le plus élevé (EUR)06-01-202517.768838.33547,1846,9647,4607-01-202516.445777.65547,2946,6647,5408-01-202517.362820.71247,2747,0647,5409-01-202515.676745.63047,5747,2647,7610-01-202517.298817.71647,2747,0047,66Total84.5494.000.04947,3146,6647,76 Depuis le lancement du programme de rachat...
Ageas rapporteert over de inkoop van eigen aandelen
Ageas rapporteert over de inkoop van eigen aandelen Naar aanleiding van het aandelen-inkoopprogramma dat op 28 augustus 2024 aangekondigd werd, maakt Ageas bekend dat er 84.549 eigen aandelen ingekocht werden tussen 06-01-2025 en 10-01-2025. DatumAantalaandelenTotaal Bedrag(EUR)Gemiddelde koers(EUR)Laagste koers(EUR)Hoogste koers(EUR)06-01-202517.768838.33547,1846,9647,4607-01-202516.445777.65547,2946,6647,5408-01-202517.362820.71247,2747,0647,5409-01-202515.676745.63047,5747,2647,7610-01-202517.298817.71647,2747,0047,66Totaal84.5494.000.04947,3146,6647,76 Vanaf de start van het aandelen-in...
ONWARD Medical to Present at the 43rd Annual J.P. Morgan Healthcare Co...
ONWARD Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference CEO Dave Marver to Provide Company Update Wednesday, January 15, 2025 EINDHOVEN, the Netherlands, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces that CEO Dave Marver will present a company update at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, Janu...
- Thomas Vranken
Onward Medical FIRST LOOK: First commercial sales for ARC-EX
Only days after its de novo FDA approval for ARC-EX in clinic use, Onward has realized its first sales of the device. The two initial customers are UW Medicine and Next Steps Chicago, which appears in line with the company's previously communicated limited launch strategy. We look forward to seeing more sales materialize over the year. We reiterate our € 10.4 TP and Buy rating.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Vranken
- Wim Lewi
ONWARD Medical Announces First Commercial Sales of ARC-EX System
ONWARD Medical Announces First Commercial Sales of ARC-EX System UW Medicine and Next Steps Chicago both purchased systems in late December 2024 ARC-EX is the first and only FDA approved technology indicated to improve hand strength and sensation in people with spinal cord injury ARC-EX was named a 2024 TIME Magazine Best Invention EINDHOVEN, the Netherlands, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord ...
Ageas reports on the progress of share buy-back programme
Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 21,749 Ageas shares in the period from 23-12-2024 until 27-12-2024. DateNumber ofSharesTotal amount(EUR)Average price(EUR)Lowest price(EUR)Highest price(EUR)23-12-20248,321383,15546.0545.8046.1224-12-2024-----25-12-2024-----26-12-20247,613352,51846.3046.1046.4027-12-20245,815268,46646.1745.9446.52Total21,7491,004,14046.1745.8046.52 Since the start of the share buy-back programme on 16 September 2024, Ageas has bought b...
Ageas rapporteert over de inkoop van eigen aandelen
Ageas rapporteert over de inkoop van eigen aandelen Naar aanleiding van het aandelen-inkoopprogramma dat op 28 augustus 2024 aangekondigd werd, maakt Ageas bekend dat er 21.749 eigen aandelen ingekocht werden tussen 23-12-2024 en 27-12-2024. DatumAantalaandelenTotaal Bedrag(EUR)Gemiddelde koers(EUR)Laagste koers(EUR)Hoogste koers(EUR)23-12-20248.321383.15546,0545,8046,1224-12-2024-----25-12-2024-----26-12-20247.613352.51846,3046,1046,4027-12-20245.815268.46646,1745,9446,52Totaal21.7491.004.14046,1745,8046,52 Vanaf de start van het aandelen-inkoopprogramma op 16 september 2024 heeft Ageas ee...
Ageas reports on the progress of share buy-back programme
Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 50,094 Ageas shares in the period from 16-12-2024 until 20-12-2024. DateNumber ofSharesTotal amount(EUR)Average price(EUR)Lowest price(EUR)Highest price(EUR)16-12-20249,450448,07347.4247.3047.7817-12-20249,234433,16346.9146.7047.3218-12-20249,690449,62146.4046.1046.9219-12-20249,720447,01445.9945.7046.1820-12-202412,000550,18745.8545.5446.20Total50,0942,328,05846.4745.5447.78 Since the start of the share buy-back progr...
Rapport d’Ageas sur le programme de rachat d’actions
Rapport d’Ageas sur le programme de rachat d’actions Dans le cadre du programme de rachat d’actions annoncé le 28 août 2024, Ageas indique que 50.094 actions Ageas ont été achetées durant la période du 16-12-2024 au 20-12-2024. DateNombred’actionsMontant total(EUR)Cours moyen(EUR)Cours le plus bas (EUR)Cours le plus élevé (EUR)16-12-20249.450448.07347,4247,3047,7817-12-20249.234433.16346,9146,7047,3218-12-20249.690449.62146,4046,1046,9219-12-20249.720447.01445,9945,7046,1820-12-202412.000550.18745,8545,5446,20Total50.0942.328.05846,4745,5447,78 Depuis le lancement du programme de rachat d’a...
Ageas rapporteert over de inkoop van eigen aandelen
Ageas rapporteert over de inkoop van eigen aandelen Naar aanleiding van het aandelen-inkoopprogramma dat op 28 augustus 2024 aangekondigd werd, maakt Ageas bekend dat er 50.094 eigen aandelen ingekocht werden tussen 16-12-2024 en 20-12-2024. DatumAantalaandelenTotaal Bedrag(EUR)Gemiddelde koers(EUR)Laagste koers(EUR)Hoogste koers(EUR)16-12-20249.450448.07347,4247,3047,7817-12-20249.234433.16346,9146,7047,3218-12-20249.690449.62146,4046,1046,9219-12-20249.720447.01445,9945,7046,1820-12-202412.000550.18745,8545,5446,20Totaal50.0942.328.05846,4745,5447,78 Vanaf de start van het aandelen-inkoop...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Thomas Vranken
Onward Medical A long-awaited present underneath the Christmas tree
Right in line with its YE24 guidance, Onward has successfully obtained FDA approval for its non-invasive ARC-EX device. We see the approval as an important inflection point and expect a phased, relatively de-risked launch given the concentrated patient population and Onward's partnership with Lovell. Although home use is not yet included in the label, we believe this could be addressed in 2025 without additional clinical study requirements. We adjust our TP from € 8.7 to € 10.4 and reiterate a B...
ONWARD Medical Receives FDA De Novo Classification and US Market Autho...
ONWARD Medical Receives FDA De Novo Classification and US Market Authorization for World’s First Non-Invasive Spinal Cord Stimulation System for People with Chronic Spinal Cord Injury THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) ARC-EX System is the first and only FDA approved technology shown to improve hand strength and sensation after chronic spinal cord injury ARC-EX System is an FDA Breakthrough Device and 2024 TIME Magazine Best Invention EINDHOVEN, the Netherlands, Dec. 19, 2024 (GLOBE NEWS...
ONWARD® Medical reçoit la classification De Novo de la FDA et l'autori...
ONWARD® Medical reçoit la classification De Novo de la FDA et l'autorisation de mise sur le marché américain pour le premier système non invasif au monde de stimulation de la moelle épinière destiné aux personnes atteintes de lésion chronique de la moelle épinière CE COMMUNIQUÉ DE PRESSE CONTIENT DES INFORMATIONS PRIVÉES AU SENS DE L'ARTICLE (7)(1) DU RÈGLEMENT EUROPÉEN SUR LES ABUS DE MARCHÉ (596/2014) Le système ARC-EX® est la première et unique technologie approuvée par la FDA ayant démontré une amélioration de la force et de la sensation des mains après une lésion chronique de la moell...
Ageas and The Goldman Sachs Group, Inc: Transparency notification
Ageas and The Goldman Sachs Group, Inc: Transparency notification In accordance with the rules on financial transparency*, The Goldman Sachs Group, Inc has notified Ageas on 13 December 2024 that, on 9 December 2024, its interest has fallen below the legal threshold of 5% of the shares issued by Ageas. On 12 December 2024 it notified Ageas that, on 6 December 2024, its interest has fallen below the statutory threshold of 3% of shares issued by Ageas in box A (Voting rights). Its current shareholding stands at 0.35%. Reason for the notification of 13 December 2024Acquisition or disposal of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.